Overview
Spherix’s coverage of emerging neurology indications focuses on evolving markets where a paradigm shift is expected in the coming years.
Services Available
Prepping for the pipeline
Alzheimer's Disease (US)
Amyotrophic Lateral Sclerosis (US)
Neuromyelitis Optica Spectrum Disorder (US)
Myasthenia Gravis (US)
Benchmarking new brand performance
Aduhelm (Biogen) in Alzheimer's Disease (US)
Donanemab (Eli Lilly) in Alzheimer’s Disease (US)*
Lecanemab (Eisai/Biogen) in Alzheimer’s Disease (US)*
*Pending approvals and launch